A combination of polymorphic mutations in V3 loop of HIV-1 gp120 can confer noncompetitive resistance to maraviroc

Virology

Volumn 413, Issue 2, 2011, Pages 293-299

  Yuan, Yuzhe ^a   Maeda, Yosuke ^a   Terasawa, Hiromi ^a   Monde, Kazuaki ^a   Harada, Shinji ^a   Yusa, Keisuke ^b  

^a KUMAMOTO UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

CCR5; Gp120; HIV 1; Maraviroc; Noncompetitive resistance; V3 loop; Viral entry

Indexed keywords

GLYCOPROTEIN GP 120; MARAVIROC;

ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; VIRUS ISOLATION; VIRUS MUTATION;

AMINO ACID SEQUENCE; ANTI-HIV AGENTS; CELL LINE; CYCLOHEXANES; DRUG RESISTANCE, VIRAL; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; MUTATION; POLYMORPHISM, GENETIC; TRIAZOLES; VIRUS INTERNALIZATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79954631299     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2011.02.019     Document Type: Article

References (33)

1. Baba M., Miyake H., Wang X., Okamoto M., Takashima K. Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652. Antimicrob. Agents Chemother. 2007, 51(2):707-715.
2. Berro R., Sanders R.W., Lu M., Klasse P.J., Moore J.P. Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry. PLoS Pathog. 2009, 5(8):e1000548.
3. Chan D.C., Kim P.S. HIV entry and its inhibition. Cell 1998, 93(5):681-684.
4. Chan D.C., Fass D., Berger J.M., Kim P.S. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997, 89(2):263-273.
5. Donzella G.A., Schols D., Lin S.W., Este J.A., Nagashima K.A., Maddon P.J., Allaway G.P., Sakmar T.P., Henson G., De Clercq E., Moore J.P. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat. Med. 1998, 4(1):72-77.
6. Dorr P., Westby M., Dobbs S., Griffin P., Irvine B., Macartney M., Mori J., Rickett G., Smith-Burchnell C., Napier C., Webster R., Armour D., Price D., Stammen B., Wood A., Perros M. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 2005, 49(11):4721-4732.
7. Dragic T., Trkola A., Thompson D.A., Cormier E.G., Kajumo F.A., Maxwell E., Lin S.W., Ying W., Smith S.O., Sakmar T.P., Moore J.P. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc. Natl Acad. Sci. USA 2000, 97(10):5639-5644.
8. Fatkenheuer G., Pozniak A.L., Johnson M.A., Plettenberg A., Staszewski S., Hoepelman A.I., Saag M.S., Goebel F.D., Rockstroh J.K., Dezube B.J., Jenkins T.M., Medhurst C., Sullivan J.F., Ridgway C., Abel S., James I.T., Youle M., van der Ryst E. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat. Med. 2005, 11(11):1170-1172.
9. Gulick R.M., Su Z., Flexner C., Hughes M.D., Skolnik P.R., Wilkin T.J., Gross R., Krambrink A., Coakley E., Greaves W.L., Zolopa A., Reichman R., Godfrey C., Hirsch M., Kuritzkes D.R. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. J. Infect. Dis. 2007, 196(2):304-312.
10. Hachiya A., Aizawa-Matsuoka S., Tanaka M., Takahashi Y., Ida S., Gatanaga H., Hirabayashi Y., Kojima A., Tatsumi M., Oka S. Rapid and simple phenotypic assay for drug susceptibility of human immunodeficiency virus type 1 using CCR5-expressing HeLa/CD4(+) cell clone 1-10 (MAGIC-5). Antimicrob. Agents Chemother. 2001, 45(2):495-501.
11. Henrich T.J., Tsibris A.M., Lewine N.R., Konstantinidis I., Leopold K.E., Sagar M., Kuritzkes D.R. Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate. J. Acquir. Immune Defic. Syndr. 2010, 55(4):420-427.
12. Kuhmann S.E., Hartley O. Targeting chemokine receptors in HIV: a status report. Annu. Rev. Pharmacol. Toxicol. 2008, 48:425-461.
13. Kuhmann S.E., Pugach P., Kunstman K.J., Taylor J., Stanfield R.L., Snyder A., Strizki J.M., Riley J., Baroudy B.M., Wilson I.A., Korber B.T., Wolinsky S.M., Moore J.P. Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J. Virol. 2004, 78(6):2790-2807.
14. Lusso P., Earl P.L., Sironi F., Santoro F., Ripamonti C., Scarlatti G., Longhi R., Berger E.A., Burastero S.E. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains. J. Virol. 2005, 79(11):6957-6968.
15. MacArthur R.D., Novak R.M. Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents. Clin. Infect. Dis. 2008, 47(2):236-241.
16. Maeda Y., Foda M., Matsushita S., Harada S. Involvement of both the V2 and V3 regions of the CCR5-tropic human immunodeficiency virus type 1 envelope in reduced sensitivity to macrophage inflammatory protein 1alpha. J. Virol. 2000, 74(4):1787-1793.
17. Maeda Y., Yusa K., Harada S. Altered sensitivity of an R5X4 HIV-1 strain 89.6 to coreceptor inhibitors by a single amino acid substitution in the V3 region of gp120. Antiviral. Res. 2008, 77(2):128-135.
18. Marozsan A.J., Kuhmann S.E., Morgan T., Herrera C., Rivera-Troche E., Xu S., Baroudy B.M., Strizki J., Moore J.P. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology 2005, 338(1):182-199.
19. Monde K., Maeda Y., Tanaka Y., Harada S., Yusa K. Gp120 V3-dependent impairment of R5 HIV-1 infectivity due to virion-incorporated CCR5. J. Biol. Chem. 2007, 282(51):36923-36932.
20. Moore J.P., Kuritzkes D.R. A piece de resistance: how HIV-1 escapes small molecule CCR5 inhibitors. Curr. Opin. HIV AIDS 2009, 4(2):118-124.
21. Ogert R.A., Wojcik L., Buontempo C., Ba L., Buontempo P., Ralston R., Strizki J., Howe J.A. Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120. Virology 2008, 373(2):387-399.
22. Ogert R.A., Hou Y., Ba L., Wojcik L., Qiu P., Murgolo N., Duca J., Dunkle L.M., Ralston R., Howe J.A. Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5. Virology 2010, 400(1):145-155.
23. Pastore C., Ramos A., Mosier D.E. Intrinsic obstacles to human immunodeficiency virus type 1 coreceptor switching. J. Virol. 2004, 78(14):7565-7574.
24. Pauwels R., Balzarini J., Baba M., Snoeck R., Schols D., Herdewijn P., Desmyter J., De Clercq E. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 1988, 20(4):309-321.
25. Pugach P., Marozsan A.J., Ketas T.J., Landes E.L., Moore J.P., Kuhmann S.E. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology 2007, 361(1):212-228.
26. Strizki J.M., Xu S., Wagner N.E., Wojcik L., Liu J., Hou Y., Endres M., Palani A., Shapiro S., Clader J.W., Greenlee W.J., Tagat J.R., McCombie S., Cox K., Fawzi A.B., Chou C.C., Pugliese-Sivo C., Davies L., Moreno M.E., Ho D.D., Trkola A., Stoddart C.A., Moore J.P., Reyes G.R., Baroudy B.M. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc. Natl Acad. Sci. USA 2001, 98(22):12718-12723.
27. Trkola A., Kuhmann S.E., Strizki J.M., Maxwell E., Ketas T., Morgan T., Pugach P., Xu S., Wojcik L., Tagat J., Palani A., Shapiro S., Clader J.W., McCombie S., Reyes G.R., Baroudy B.M., Moore J.P. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc. Natl Acad. Sci. USA 2002, 99(1):395-400.
28. Tsibris A.M., Kuritzkes D.R. Chemokine antagonists as therapeutics: focus on HIV-1. Annu. Rev. Med. 2007, 58:445-459.
29. Tsibris A.M., Sagar M., Gulick R.M., Su Z., Hughes M., Greaves W., Subramanian M., Flexner C., Giguel F., Leopold K.E., Coakley E., Kuritzkes D.R. In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. J. Virol. 2008, 82(16):8210-8214.
30. Westby M., van der Ryst E. CCR5 antagonists: host-targeted antiviral agents for the treatment of HIV infection, 4years on. Antivir. Chem. Chemother. 2010, 20(5):179-192.
31. Westby M., Smith-Burchnell C., Mori J., Lewis M., Mosley M., Stockdale M., Dorr P., Ciaramella G., Perros M. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J. Virol. 2007, 81(5):2359-2371.
32. Wild C., Greenwell T., Matthews T. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res. Hum. Retroviruses 1993, 9(11):1051-1053.
33. Yusa K., Maeda Y., Fujioka A., Monde K., Harada S. Isolation of TAK-779-resistant HIV-1 from an R5 HIV-1 GP120 V3 loop library. J. Biol. Chem. 2005, 280(34):30083-30090.